- Home
- ECBK vs ALDX Comparison
ECBK vs ALDX Comparison
Compare ECBK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- ALDX
- Stock Information
- Founded
- ECBK 1919
- ALDX 2004
- Country
- ECBK United States
- ALDX United States
- Employees
- ECBK N/A
- ALDX N/A
- Industry
- ECBK Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- ALDX Health Care
- Exchange
- ECBK Nasdaq
- ALDX Nasdaq
- Market Cap
- ECBK 151.0M
- ALDX 160.8M
- IPO Year
- ECBK N/A
- ALDX 2014
- Fundamental
- Price
- ECBK $16.20
- ALDX $4.76
- Analyst Decision
- ECBK
- ALDX Strong Buy
- Analyst Count
- ECBK 0
- ALDX 2
- Target Price
- ECBK N/A
- ALDX $9.50
- AVG Volume (30 Days)
- ECBK 67.4K
- ALDX 1.2M
- Earning Date
- ECBK 08-08-2025
- ALDX 07-31-2025
- Dividend Yield
- ECBK N/A
- ALDX N/A
- EPS Growth
- ECBK 17.87
- ALDX N/A
- EPS
- ECBK 0.57
- ALDX N/A
- Revenue
- ECBK $26,906,000.00
- ALDX N/A
- Revenue This Year
- ECBK N/A
- ALDX N/A
- Revenue Next Year
- ECBK N/A
- ALDX N/A
- P/E Ratio
- ECBK $28.23
- ALDX N/A
- Revenue Growth
- ECBK 5.99
- ALDX N/A
- 52 Week Low
- ECBK $12.50
- ALDX $1.14
- 52 Week High
- ECBK $16.99
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ECBK 59.34
- ALDX 78.74
- Support Level
- ECBK $15.81
- ALDX $4.12
- Resistance Level
- ECBK $16.45
- ALDX $4.60
- Average True Range (ATR)
- ECBK 0.40
- ALDX 0.29
- MACD
- ECBK 0.11
- ALDX 0.08
- Stochastic Oscillator
- ECBK 81.85
- ALDX 90.91
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.